134 related articles for article (PubMed ID: 37031090)
1. Urine Drug Test Results Among Adolescents and Young Adults in an Outpatient Office-Based Opioid Treatment Program.
Ramey OL; Bonny AE; Silva Almodóvar A; Nahata MC
J Adolesc Health; 2023 Jul; 73(1):141-147. PubMed ID: 37031090
[TBL] [Abstract][Full Text] [Related]
2. Opioid and cocaine use among primary care patients on buprenorphine-Self-report and urine drug tests.
Bagley SM; Cheng DM; Winter M; Alford DP; LaBelle C; Walley AY; Samet JH
Drug Alcohol Depend; 2018 Nov; 192():245-249. PubMed ID: 30290291
[TBL] [Abstract][Full Text] [Related]
3. Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine.
LaRue L; Twillman RK; Dawson E; Whitley P; Frasco MA; Huskey A; Guevara MG
JAMA Netw Open; 2019 Apr; 2(4):e192851. PubMed ID: 31026029
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Urine Drug Test Results From Substance Use Disorder Treatment Practices and Overdose Mortality Rates, 2013-2020.
Whitley P; LaRue L; Fernandez SA; Passik SD; Dawson E; Jackson RD
JAMA Netw Open; 2022 Jun; 5(6):e2215425. PubMed ID: 35657623
[TBL] [Abstract][Full Text] [Related]
5. Methamphetamine use and illicit opioid use during buprenorphine treatment.
Kratina-Hathaway Z; Radick AC; Leroux BG; Blalock K; Kim TW; Darnton J; Saxon AJ; Samet JH; Tsui JI
J Subst Use Addict Treat; 2023 Aug; 151():. PubMed ID: 37811395
[TBL] [Abstract][Full Text] [Related]
6. Do Urine Drug Tests Reveal Substance Misuse Among Patients Prescribed Opioids for Chronic Pain?
Larochelle MR; Cruz R; Kosakowski S; Gourlay DL; Alford DP; Xuan Z; Krebs EE; Yan S; Lasser KE; Samet JH; Liebschutz JM
J Gen Intern Med; 2022 Aug; 37(10):2365-2372. PubMed ID: 34405344
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
[TBL] [Abstract][Full Text] [Related]
8. Retention in Office-Based Opioid Treatment and Impact on Emergency Department Use in Adolescents and Young Adults With Opioid Use Disorder.
Ramey OL; Bonny AE; Silva Almodóvar A; Nahata MC
J Adolesc Health; 2023 Jul; 73(1):148-154. PubMed ID: 37032210
[TBL] [Abstract][Full Text] [Related]
9. Chronic opioid therapy urine drug testing in primary care: prevalence and predictors of aberrant results.
Turner JA; Saunders K; Shortreed SM; LeResche L; Riddell K; Rapp SE; Von Korff M
J Gen Intern Med; 2014 Dec; 29(12):1663-71. PubMed ID: 25217208
[TBL] [Abstract][Full Text] [Related]
10. Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database.
Saloner B; Whitley P; LaRue L; Dawson E; Huskey A
JAMA Netw Open; 2021 Sep; 4(9):e2123019. PubMed ID: 34505888
[TBL] [Abstract][Full Text] [Related]
11. Long-term retention in Office Based Opioid Treatment with buprenorphine.
Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
[TBL] [Abstract][Full Text] [Related]
12. Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results.
Turner JA; Saunders K; Shortreed SM; Rapp SE; Thielke S; LeResche L; Riddell KM; Von Korff M
J Gen Intern Med; 2014 Feb; 29(2):305-11. PubMed ID: 24142119
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.
Ray-Griffith S; Tharp E; Coker JL; Catlin D; Knight B; Stowe ZN
Am J Addict; 2021 Jan; 30(1):43-48. PubMed ID: 32673447
[TBL] [Abstract][Full Text] [Related]
14. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
[TBL] [Abstract][Full Text] [Related]
15. Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified.
Wyse JJ; Morasco BJ; Dobscha SK; Demidenko MI; Meath THA; Lovejoy TI
J Opioid Manag; 2018; 14(4):295-303. PubMed ID: 30234926
[TBL] [Abstract][Full Text] [Related]
16. Frequency, predictors, and outcomes of urine drug testing among patients with advanced cancer on chronic opioid therapy at an outpatient supportive care clinic.
Arthur JA; Edwards T; Lu Z; Reddy S; Hui D; Wu J; Liu D; Williams JL; Bruera E
Cancer; 2016 Dec; 122(23):3732-3739. PubMed ID: 27509305
[TBL] [Abstract][Full Text] [Related]
17. Treatment changes following aberrant urine drug test results for patients prescribed chronic opioid therapy.
Morasco BJ; Krebs EE; Cavanagh R; Hyde S; Crain A; Dobscha SK
J Opioid Manag; 2015; 11(1):45-51. PubMed ID: 25750164
[TBL] [Abstract][Full Text] [Related]
18. Utility of the Pain Medication Questionnaire to predict aberrant urine drug tests: Results from a longitudinal cohort study.
Morasco BJ; Iacocca MO; Lovejoy TI; Dobscha SK; Deyo RA; Cavese JA; Hyde S; Yarborough BJH
Psychol Serv; 2021 Aug; 18(3):319-327. PubMed ID: 32673038
[TBL] [Abstract][Full Text] [Related]
19. Urine Drug Testing among Opioid-Naïve and Long-Term Opioid Nevada Medicaid Beneficiaries.
Friedman S; Patel K; Liu Y; Hartzell S; Keller MS
Subst Use Misuse; 2020; 55(14):2314-2320. PubMed ID: 32835582
[TBL] [Abstract][Full Text] [Related]
20. Physician Renewal of Chronically Prescribed Controlled Substances Based on Urine Drug Test Results.
Hosain F; Lee J; Ata A; Bhullar RK; Chang AK
J Prim Care Community Health; 2019; 10():2150132719883632. PubMed ID: 31646927
[No Abstract] [Full Text] [Related]
[Next] [New Search]
